Dr. Roger Zemek explores differences in concussion symptoms
Dr. Roger Zemek was the lead researcher on a comprehensive study involving more than 3,000 children between ages 5 and 18. More than 8,000 children were screened for this study, which was published in the Journal of the American Medical Association (JAMA) in 2016 and gathered data from five centres, including Ottawa.
Dr. Schlossmacher honoured with the 2017 Grimes Research Career Achievement Award
Dr. Michael Schlossmacher grew up in Austria, trained at Harvard and now leads The Ottawa Hospital’s neuroscience research program. His research helped establish a key concept in Alzheimer’s disease and led to a clinical trial of an experimental therapy for Parkinson’s. He is now investigating the link between Parkinson’s and immune system. He will receive the Grimes Research Career Achievement Award from the hospital on October 28, 2017.
$10 million boost for research on neuromuscular diseases and virus-based therapies
Ottawa researchers have been awarded nearly $10 million from the Canada Foundation for Innovation for new equipment and facilities to support cutting-edge research on neuromuscular diseases and virus-based therapies. “This funding will help us build on recent breakthroughs in our understanding of neuromuscular diseases, design much-needed new therapies and evaluate them in patients,” said Dr. Rashmi Kothary, who leads the $4 million neuromuscular project together with Dr. Bernard Jasmin.
Award-winning tool helps predict course of recovery from spinal cord injury
“Will I ever walk again?” is one of the first questions a person asks after a spinal cord injury. Because each person’s recovery is different, it’s often hard for physicians to predict what an individual will be able to do in the future. Dr. Philippe Phan’s team, including Drs. Eugene Wai, Eve Tsai and Darren Roffey and contributors from across the country, has made answering this question easier by simplifying an existing prediction tool.
Extra maternal care prevents brain inflammation and reduces anxiety in mice
New research led by Dr. Hsiao-Huei Chen reveals that a protein called IRF2BP2 plays an important role in controlling anxiety in mice by influencing microglia, known as the immune system of the brain. Microglial cells can do many things, including fighting infections, promoting inflammation, gobbling up damaged or unwanted brain cells and encouraging healing.
Dr. Johnny Ngsee’s team has created the first worm model of a genetic form of ALS called ALS8 that can be used to learn more about the disease and test possible therapies. ALS, or Amyotrophic Lateral Sclerosis, is caused by the gradual death of the nerves that control the muscles. There is no prevention or cure, and 80 percent of people with ALS die within two to five years of being diagnosed. Dr. Ngsee’s team created worms with a genetic mutation that mimics the disease.